RNA Outsourcing Articles

1. Is mRNA Manufacturing Overbuilt? 9/15/2026

   mRNA pipelines continue to advance, but has provider growth outpaced the pipeline? Let's take a closer look.

2. What Oligo Manufacturing Risks Are We Underestimating? 9/8/2026

   Earlier this year, I attended the OPT Congress, where I had the great fortune of meeting consultant Marc Lemaitre. I recently sat down with Lemaitre for a follow-up interview to gauge some of the evolutions he’s been watching within the CMC landscape for oligo development. Here, he digs into the shifts in quality he’s noted, pointing out some of the potential pitfalls we may encounter in our manufacturing that could stand to impact the overall quality of our oligos. 

3. Bridging The Atlantic: A European Executive's Guide To Building A Successful U.S. RNA Business (Pt. 2) 8/6/2026

   European RNA biotech leaders can accelerate U.S. success by aligning fundraising, partnerships, manufacturing, hiring, and regulatory strategy from day one.

4. The Delivery Challenge For In Vivo Cell Engineering 7/30/2026

   As RNA therapies expand beyond the liver, delivery—not payload design—has become the defining challenge for precise, scalable in vivo cell engineering.

5. Soliman Says… 5 Questions Every RNA Platform Must Answer Before Investors Write The Check 7/21/2026

   A practical framework for evaluating whether an RNA company has the science, strategy, scalability, and discipline to become a lasting platform.

6. Bridging The Atlantic: A European Executive's Guide To Entering The U.S. RNA Market (Pt. 1) 7/13/2026

   A practical roadmap for European biotech leaders navigating FDA expectations, market entry, and the strategic decisions that shape U.S. expansion.

7. The Hidden Bottleneck In Advanced Therapies Isn't Science… It's Translational Friction 6/26/2026

   Scientific breakthroughs may spark innovation, but operational excellence ultimately determines which advanced therapies reach patients.

8. RNA Therapeutics: Why CMC Strategy Will Define The Next Decade 6/25/2026

   As RNA matures into an industrial platform, long-term success will depend less on discovery and more on scalable CMC systems, integration, and execution.

9. How Informal FDA Feedback Is Quietly Driving RNA Capital Allocation 3/19/2026

   Subtle FDA signals — especially in pre-IND talks — are quietly shaping RNA investment. Early regulatory feedback on CMC and comparability now drives how investors assess risk and allocate capital.

10. 2026 RNA Investment Landscape: Recent Deals, IPOs, And Venture Trends 2/22/2026

    As RNA investing matures, capital is flowing toward delivery, durability, and regulatory credibility. This column breaks down the deals, IPO signals, and venture theses shaping RNA’s 2026 winners—and why.